Compare Stocks: TTRX, ARDX, IVA, and PCRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.89 -0.3%	$5.08	$3.86 ▼ $8.40	$969.35M	0.7	4.29 million shs	2.88 million shs
IVA Inventiva	$4.68 +0.6%	$4.25	$3.35 ▼ $7.98	$972.07M	0.7	655,684 shs	461,396 shs
PCRX Pacira BioSciences	$24.67 +3.5%	$24.85	$18.80 ▼ $27.66	$983.40M	0.27	691,492 shs	465,764 shs
TTRX Turn Therapeutics	$9.46 -0.8%	$8.38	$2.57 ▼ $26.50	$281.81M	N/A	50,766 shs	22,225 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	-3.23%	-0.26%	-23.38%	-36.17%	-34.89%
IVA Inventiva	-2.31%	+1.09%	+3.79%	-8.28%	+1.53%
PCRX Pacira BioSciences	-2.18%	+2.80%	-7.56%	+2.06%	-4.64%
TTRX Turn Therapeutics	-2.85%	-3.25%	-6.29%	+85.96%	+953,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.89 -0.3%	$5.08	$3.86 ▼ $8.40	$969.35M	0.7	4.29 million shs	2.88 million shs
IVA Inventiva	$4.68 +0.6%	$4.25	$3.35 ▼ $7.98	$972.07M	0.7	655,684 shs	461,396 shs
PCRX Pacira BioSciences	$24.67 +3.5%	$24.85	$18.80 ▼ $27.66	$983.40M	0.27	691,492 shs	465,764 shs
TTRX Turn Therapeutics	$9.46 -0.8%	$8.38	$2.57 ▼ $26.50	$281.81M	N/A	50,766 shs	22,225 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	-3.23%	-0.26%	-23.38%	-36.17%	-34.89%
IVA Inventiva	-2.31%	+1.09%	+3.79%	-8.28%	+1.53%
PCRX Pacira BioSciences	-2.18%	+2.80%	-7.56%	+2.06%	-4.64%
TTRX Turn Therapeutics	-2.85%	-3.25%	-6.29%	+85.96%	+953,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	2.75	Moderate Buy	$13.90	257.33% Upside
IVA Inventiva	3.09	Buy	$16.56	253.75% Upside
PCRX Pacira BioSciences	2.29	Hold	$30.20	22.42% Upside
TTRX Turn Therapeutics	2.50	Moderate Buy	$8.00	-15.43% Downside

Current Analyst Ratings Breakdown

Latest TTRX, ARDX, IVA, and PCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	TTRX Turn Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	ARDX Ardelyx	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$9.00
8/17/2026	PCRX Pacira BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
8/17/2026	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$16.00 ➝ $15.00
8/17/2026	PCRX Pacira BioSciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$30.00
8/10/2026	ARDX Ardelyx	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$14.00 ➝ $11.00
8/7/2026	ARDX Ardelyx	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$13.00 ➝ $10.00
8/7/2026	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
8/7/2026	ARDX Ardelyx	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$17.00 ➝ $14.00
8/5/2026	PCRX Pacira BioSciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$24.00 ➝ $25.00
8/5/2026	PCRX Pacira BioSciences	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $33.00

(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$407.32M	2.38	N/A	N/A	$0.60 per share	6.48
IVA Inventiva	$4.48M	216.83	N/A	N/A	($0.22) per share	-21.27
PCRX Pacira BioSciences	$746.16M	1.32	$3.91 per share	6.31	$16.86 per share	1.46
TTRX Turn Therapeutics	N/A	N/A	N/A	N/A	$0.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$61.60M	-$0.22	N/A	16.21	N/A	-12.35%	-36.00%	-10.77%	10/29/2026 (Estimated)
IVA Inventiva	-$400.67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/25/2026 (Estimated)
PCRX Pacira BioSciences	$7.03M	$0.35	70.49	10.28	N/A	1.96%	9.68%	5.30%	11/5/2026 (Estimated)
TTRX Turn Therapeutics	-$3.19M	-$0.29	N/A	N/A	N/A	N/A	-230.84%	-53.19%	N/A

Latest TTRX, ARDX, IVA, and PCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	TTRX Turn Therapeutics	N/A	-$0.20	N/A	-$0.20	N/A	N/A
8/6/2026	Q2 2026	ARDX Ardelyx	-$0.05	-$0.07	-$0.02	-$0.07	$121.04 million	$120.88 million
8/4/2026	Q2 2026	PCRX Pacira BioSciences	$0.6460	$0.73	+$0.0840	$0.12	$191.06 million	$192.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A
PCRX Pacira BioSciences	N/A	N/A	N/A	N/A	N/A
TTRX Turn Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.69	3.34	3.15
IVA Inventiva	N/A	3.16	3.16
PCRX Pacira BioSciences	0.54	5.04	3.94
TTRX Turn Therapeutics	8.83	1.19	1.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
IVA Inventiva	19.06%
PCRX Pacira BioSciences	99.73%
TTRX Turn Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	5.30%
IVA Inventiva	32.00%
PCRX Pacira BioSciences	6.40%
TTRX Turn Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	249.19 million	235.98 million	Optionable
IVA Inventiva	100	207.71 million	141.24 million	Not Optionable
PCRX Pacira BioSciences	720	39.86 million	37.31 million	Optionable
TTRX Turn Therapeutics	2	29.79 million	N/A	N/A

TTRX, ARDX, IVA, and PCRX Headlines

Recent News About These Companies

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

August 20 at 12:25 PM | finance.yahoo.com

Turn Therapeutics Reports Unregistered Cashless Warrant Share Issuance

August 18 at 9:10 AM | tipranks.com

Turn Therapeutics (NASDAQ:TTRX) Stock Price Down 6.5% - Time to Sell?

August 13, 2026 | marketbeat.com

Turn Therapeutics Inc. GAAP EPS of -$0.20

August 13, 2026 | seekingalpha.com

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

August 12, 2026 | businesswire.com

Turn Therapeutics Inc. Share Price (TTRX.US)

August 5, 2026 | lse.co.uk

Turn Therapeutics Inc.

August 2, 2026 | cnn.com

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

July 28, 2026 | businesswire.com

Zacks Research Upgrades Turn Therapeutics (NASDAQ:TTRX) to Hold

July 23, 2026 | marketbeat.com

Turn Therapeutics Inc. (TTRX)

July 11, 2026 | sg.finance.yahoo.com

Why Is Turn Therapeutics Stock Trading Higher Today?

July 7, 2026 | benzinga.com

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis

July 7, 2026 | businesswire.com

Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis

July 6, 2026 | businesswire.com

Turn Therapeutics Stock Short Interest Report | NASDAQ:TTRX | Benzinga

July 3, 2026 | benzinga.com

Turn Therapeutics appoints veteran executive to board

July 3, 2026 | theglobeandmail.com

TTRX Turn Therapeutics Inc.

June 19, 2026 | seekingalpha.com

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis

June 1, 2026 | businesswire.com

Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model

May 27, 2026 | businesswire.com

Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026

May 19, 2026 | businesswire.com

Turn Therapeutics Appoints Former FDA Chief to Lead GX-03

May 18, 2026 | tipranks.com

Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead

May 18, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TTRX, ARDX, IVA, and PCRX Company Descriptions

Ardelyx NASDAQ:ARDX

$3.89 -0.01 (-0.26%)

As of 04:00 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Inventiva NASDAQ:IVA

$4.68 +0.03 (+0.65%)

As of 04:00 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Pacira BioSciences NASDAQ:PCRX

$24.67 +0.84 (+3.52%)

As of 04:00 PM Eastern

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Turn Therapeutics NASDAQ:TTRX

$9.46 -0.08 (-0.84%)

As of 04:00 PM Eastern

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events. Our proprietary platform has been validated across multiple FDA-cleared medical devices. Our primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Our company’s origin is rooted in the personal journey of our founder, who developed a topical ointment to heal his own chronic, treatment-resistant wounds using the PermaFusion platform he developed. His initial formulation, now known as Hexagen (“Hexagen”) suspends certain antimicrobial/anti-inflammatory compounds in petrolatum without known cytotoxicity, irritation or sensitization. This formula has received three FDA clearances and has been utilized extensively in humans, which we believe demonstrates both technical proof of concept and meaningful therapeutic effects. The formula also has been demonstrated to provide anti-inflammatory immunological signaling (IL 36, IL 31, IL 4 inhibition), in-vivo nail penetration with fungal pathogen elimination, and other potential therapeutic benefits. These products are not presently on the market, and we are not currently generating revenue from these devices, as we focus on drug development of our core technology. In addition to our dermatology and wound programs, we are exploring broader applications of our PermaFusion technology. In partnership with a leading global nonprofit organization, we are attempting to develop intranasal vaccines with sufficient thermostability to withstand distribution without deep-freeze. Our goal is to eliminate the need for frozen storage and, thus, enable deployment and delivery to low-resource settings that do not maintain suitable cold storage infrastructure required for administration of modern-day vaccines. Furthermore, if we are successful in this initial program, we believe there may be opportunities to develop additional vaccines in thermostable, intranasal form. By reducing cold-storage infrastructure requirements and therefore enabling standard shipping of such vaccines, we believe intranasal vaccines have the potential to enhance patient uptake by enabling immunization in a broader variety of settings including in clinic, hospital and home-health settings. We believe this initiative highlights our platform’s versatility and its potential to unlock new therapeutic categories beyond dermatology. We have also completed preclinical, in-vivo xenograft studies for herpes zoster ophthalmicus (shingles of the eye) and basal cell carcinoma. A mildly reformulated version of the Hexagen formula was employed for the ocular study and compared this reformulation with placebo as a topical ocular agent intended to reduce viral load of herpes zoster in an animal model. Results obtained showed an 85% reduction in viral load compared to placebo without adverse events. For the basal cell carcinoma xenograft study, the Hexagen formula was compared to both placebo and 5-Fluorouracil (standard of care topical chemotherapy) as a topical treatment intended to reduce basal cell tumor size. The Hexagen formula showed an approximate 29% comparative reduction in tumor size to the placebo and an approximate 20% comparative reduction in tumor size compared to 5-Fluorouracil. We believe these preclinical in-vivo studies suggest meaningful potential in these indications, which we may continue to explore at the conclusion of our lead drug programs. We believe such exploratory results further underscore the potential breadth of opportunity enabled by our platform. We were initially formed on January 6, 2015, as Global Health Solutions, LLC, a Delaware limited liability company. On October 12, 2018, Global Health Solutions, LLC converted to a Delaware corporation under the name Global Health Solutions, Inc., dba Turn Therapeutics. Immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, we intend to change our name to Turn Therapeutics Inc. Our principal executive offices are located in Westlake Village, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TTRX, ARDX, IVA, and PCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TTRX, ARDX, IVA, and PCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TTRX, ARDX, IVA, and PCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TTRX, ARDX, IVA, and PCRX Company Descriptions

Ardelyx NASDAQ:ARDX

Inventiva NASDAQ:IVA

Pacira BioSciences NASDAQ:PCRX

Turn Therapeutics NASDAQ:TTRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TTRX, ARDX, IVA, and PCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TTRX, ARDX, IVA, and PCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TTRX, ARDX, IVA, and PCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TTRX, ARDX, IVA, and PCRX Company Descriptions

Ardelyx NASDAQ:ARDX

Inventiva NASDAQ:IVA

Pacira BioSciences NASDAQ:PCRX

Turn Therapeutics NASDAQ:TTRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools